These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10888033)

  • 21. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
    Seo MS; Kwak N; Ozaki H; Yamada H; Okamoto N; Yamada E; Fabbro D; Hofmann F; Wood JM; Campochiaro PA
    Am J Pathol; 1999 Jun; 154(6):1743-53. PubMed ID: 10362799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model.
    Saishin Y; Silva RL; Saishin Y; Callahan K; Schoch C; Ahlheim M; Lai H; Kane F; Brazzell RK; Bodmer D; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4989-93. PubMed ID: 14578426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
    Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
    Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analogs of staurosporine: potential anticancer drugs?
    Gescher A
    Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
    Luo W; Sharif TR; Houghton PJ; Sharif M
    Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
    Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
    Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.
    Begemann M; Kashimawo SA; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Anticancer Res; 1998; 18(4A):2275-82. PubMed ID: 9703866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Arzneimittelforschung; 1996 Feb; 46(2):201-4. PubMed ID: 8720314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.
    Sharkey J; Khong T; Spencer A
    Blood; 2007 Feb; 109(4):1712-9. PubMed ID: 17032922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
    Ikegami Y; Yano S; Nakao K
    Jpn J Pharmacol; 1996 Jan; 70(1):65-72. PubMed ID: 8822090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
    Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
    Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine.
    Gollapudi L; Neet KE
    J Neurosci Res; 1997 Aug; 49(4):461-74. PubMed ID: 9285522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
    Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
    Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.